China Biologic Products Holdings, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, has announced the completion of its merger with CBPO Group Limited. Latham & Watkins advised CITIC Capital, a member of the buyer consortium, in the transaction, with a cross-border team involving M&A, capital markets, and investment funds lawyers across Greater China, the US and London.
As a result of the merger, China Biologic became a wholly owned subsidiary of CBPO Holdings Limited and ceased to be a publicly traded company on Nasdaq. China Biologic’s products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases.
The M&A deal team was led by Hong Kong partner Frank Sun, with Beijing associate Haibo (Jason) Zhao. Capital markets advice was provided by Hong Kong partner Benjamin Su, Chicago partner Bradley Faris, and Washington D.C. partners William Baker, Alexander Cohen, Paul Dudek, Brian Miller and Joel Trotter. Additional advice was provided by London investment funds partner Nick Benson, with associates Olivia Kim and Robert Burke.